Cargando…
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their inci...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289164/ https://www.ncbi.nlm.nih.gov/pubmed/25471129 http://dx.doi.org/10.1186/1471-2407-14-915 |